UC San Diego won a long‑term ARPA‑H award to develop patient‑specific, 3D‑bioprinted human livers with the goal of creating transplant‑ready organs from a patient’s own cells. The five‑year, ~$25.8 million PRINT program grant will fund multidisciplinary work on vascularization, immunocompetence and scalable manufacturing that the team says are critical barriers to clinical translation. Principal investigators, led by Shaochen Chen, plan to combine rapid high‑resolution bioprinting with AI‑driven vascular design to address perfusion and integration challenges. The project aims to eliminate the need for lifelong immunosuppression by using autologous cells and to provide an alternative to donor organs for end‑stage liver disease. Investigators framed the program as a translational, system‑level effort that couples engineering, cell biology and regulatory planning; deliverables include preclinical validation and manufacturing process development that could underpin eventual IND filings.